Clinical trial · Observational
Hepassocin Levels in Patients With Polycystic Ovary Syndrome
NCT04369248CI-TRIAL-00044914completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators aimed to investigate hepassocin levels in patients with polycystic ovary syndrome (PCOS). There are 3 groups aged between 18 and 35 years as non-obese healthy women, non-obese women with PCOS, and obese women (BMI\>30) with PCOS.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepassocin (Hepatocyte-derived Fibrinogen-related Protein 1) | — | UNRESOLVED | — |
| Insulin Resistance | — | UNRESOLVED | — |
| Obesity | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| hepassocin | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Control group
- description
- 30 healthy women with BMI \< 30 between 18 and 35 years old
- interventionNames
- Other: hepassocin
- label
- Non-obese PCOS
- description
- 2003 Rotterdam ESHRE/ASRM PCOS Consensus Criteria were used to diagnose PCOS that fulfilled at least two of the followings: chronic oligo-anovulation, clinic or biochemical hyperandrogenism and presence of polycyctic ovary by ultrasound (Rotterdam). Oligo-anovulation is defined as periods lasting more than 35 days and/or amenorrhea. Clinic or biochemical hyperandrogenism is defined as the presence of acnes and/ or Ferriman-Galleway modified score \>8 and/ or hyperandrogenemia defining the testosterone level \> 0.6 ng/ml (2 nmol/l) and/or dehydroepiandrosterone level \> 3 ng/ml (10.5 nmol/l). Polycyctic ovaries are defined as the presence of more than 12 follicules 2-9 mm in diameters or ovarian volume \>10 cm3 under transvaginal or abdominal ultrasound. non-obese group are the women BMI \< 30 between age of 18 and 35.
- interventionNames
- Other: hepassocin
- label
- Obese PCOS
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * 60 patients with PCOS aged between 18 and 35 and age-matched 30 healthy women with BMI\<30 Exclusion Criteria: Premature ovarian failure (FSH \>30 mIU/mL), tumors secreting androgens, non-classical congenital adrenal hyperplasia, Cushing syndrome and irregular menses due to thyroid dysfunction (TSH \>5 mIU/L ), hyperprolactinemia, more than twofold high transaminase levels (\>70 U/L), patients with cigarette smoking, alcohol consumption, oral contraceptives use, medications that are affecting liver function test, insulin metabolism and lipid metabolism, patients with a history of chronic diseases such as diabetes mellitus, hypertension, chronic liver disease, chronic kidney disease, autoimmune disease, inflammatory disease, malignant disease, bleeding disorders, and thrombosis were also excluded. All the patients were beta-HCG, hepatitis B surface antigen, and hepatitis C antibody negative. \-
References
Publications (0)
Data not yet available
No reference posted for this study.